Adage Capital Partners Gp, L.L.C. Spring Works Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$24.1 - $39.66 $10.2 Million - $16.9 Million	-425,000 Reduced 73.91%	150,000 $4.28 Million
Q2 2022 Aug 15, 2022	SELL	$18.36 - $60.07 $23.9 Million - $78.1 Million	-1,300,666 Reduced 69.34%	575,000 $14.2 Million
Q1 2022 May 16, 2022	BUY	$48.97 - $65.46 $63.6 Million - $85 Million	1,299,214 Added 225.38%	1,875,666 $106 Million
Q4 2021 Feb 14, 2022	SELL	$53.3 - $75.84 $10.1 Million - $14.4 Million	-189,466 Reduced 24.74%	576,452 $35.7 Million
Q3 2021 Nov 15, 2021	BUY	$62.66 - $88.26 $12.7 Million - $17.9 Million	202,450 Added 35.93%	765,918 $48.6 Million
Q2 2021 Aug 16, 2021	SELL	$67.45 - $85.63 $301,299 - $382,509	-4,467 Reduced 0.79%	563,468 $46.4 Million
Q1 2021 May 17, 2021	BUY	$65.1 - $93.59 $17.8 Million - $25.6 Million	273,935 Added 93.18%	567,935 $41.8 Million
Q4 2020 Feb 16, 2021	BUY	$48.36 - $77.92 $14.2 Million - $22.9 Million	294,000 New	294,000 $21.3 Million

234

69.6M

145K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $3.66B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.